Skip to main content
F&S Reports logoLink to F&S Reports
editorial
. 2026 Jul 2;7(4):258–259. doi: 10.1016/j.xfre.2026.06.006

Embryo law has entered the mainstream: why reproductive medicine must engage the debate

Commentary from the ASRM Center for Policy & Leadership Following Harvard Law School’s 2026 Conference on Embryo Law and Ethics

Rebecca W O’Connor 1
PMCID: PMC13494608  PMID: 42630777

In June 2026, scholars, attorneys, ethicists, clinicians, policymakers, researchers, and advocates gathered at Harvard Law School for the Petrie-Flom Center’s Annual Conference, Embryo Law and Ethics. Organized by I. Glenn Cohen, Susannah Baruch, Judith Daar, and O. Carter Snead, and cosponsored by American Society for Reproductive Medicine’s (ASRM) Center for Policy & Leadership (CPL), the conference examined several consequential questions confronting reproductive medicine today: What is the legal status of an embryo? How should law and policy address embryo disposition, embryo research, genetic technologies, and emerging scientific advances? And who should help answer those questions?

The most important takeaway was not a particular legal theory or policy proposal. It was the recognition that embryo law has moved from the margins of academic debate to the center of reproductive healthcare and related social and political debate.

Not long ago, questions surrounding embryo status were largely confined to law reviews, bioethics journals, and academic conferences. Today, they are increasingly shaping legislation, litigation, and clinical practice. The 2024 Alabama Supreme Court decision in LePage v. Center for Reproductive Medicine illustrated how quickly abstract legal theories can affect real-world care (LePage v. Center for Reproductive Medicine, Supreme Court of Alabama [2024]). What began as a wrongful death case became a national debate over the legal status of embryos and the future of in vitro fertilization (IVF). Clinics paused treatment, patients faced uncertainty, and policymakers across the country began advancing similar proposals.

Recent federal developments further illustrate how rapidly embryo-related policy is evolving. In 2026, revisions to Health and Human Services’ (HHS) Embryo Adoption Awareness and Services program renewed debate about the role of embryo adoption in family-building; policy and the implications of federal language surrounding cryopreserved embryos (U.S. Department of HHS, Office of Population Affairs. About the Embryo Adoption Awareness and Services Program). The discussion also reflects the increasingly contested relationship between efforts to expand family-building options and proposals that may advance broader embryo personhood frameworks. Regardless of one's perspective, the episode underscores a central theme of the conference: questions once confined to academic debate are increasingly shaping federal reproductive health policy.

The lesson was unmistakable: questions once considered theoretical now carry immediate consequences for patients, healthcare professionals, and the practice of reproductive medicine itself.

That reality formed the backdrop for much of the discussion at Harvard. Across conversations on embryo personhood, embryo disposition disputes, artificial intelligence and embryo selection, stem-cell-derived embryo models, reproductive autonomy, and comparative approaches to regulation, a common theme emerged (Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. Embryo Law and Ethics: 2026 Annual Conference. Harvard Law School). Questions involving embryos are no longer isolated legal or ethical curiosities. They increasingly shape the environment in which reproductive medicine is practiced.

A second observation emerged just as clearly: reproductive healthcare cannot be effectively siloed.

Throughout the conference, discussions repeatedly crossed traditional policy boundaries. Conversations about abortion law, including the impact of the US Supreme Court’s Dobbs decision, intersected with discussions about IVF (Dobbs v. Jackson Women's Health Organization, 597 U.S. 215 [2022]). Questions surrounding embryo research informed discussions about genetic testing. Constitutional law, family law, medical ethics, and healthcare regulation proved deeply intertwined.

For clinicians and patients, these intersections are unsurprising. Reproductive healthcare exists on a continuum. Yet policymakers often approach these issues as though they are distinct domains. Laws intended to regulate one aspect of reproductive healthcare frequently create unintended consequences elsewhere. As lawmakers continue to grapple with embryo-related questions, understanding this broader reproductive health ecosystem will be essential.

The conference also highlighted a third lesson: meaningful engagement must occur before policy is written.

The value of the conference did not stem from consensus. Participants represented diverse disciplines and often held sharply different views regarding embryo status, regulation, and governance. Legal scholars, ethicists, physicians, scientists, and policy experts approached these questions from different professional and philosophical perspectives. That diversity was precisely what made the conversation valuable.

Questions involving embryos cannot be adequately addressed through a single disciplinary lens. Scientific capabilities are advancing rapidly. Legal frameworks struggle to keep pace. Ethical considerations evolve alongside technological innovation. Sound policymaking requires engagement across all relevant domains.

For the ASRM CPL, this reality explains why sponsoring the conference mattered (ASRM CPL sponsors Petrie-Flom Center's Annual Conference on Embryo Law and Ethics. ASRM News Release. June 2026). Some of the most significant challenges facing reproductive medicine today are rooted not in scientific uncertainty, but in legal and policy debates. Bringing together experts from different fields creates opportunities to examine difficult questions before they become entrenched political disputes or restrictive legal frameworks.

This is particularly important at a moment when embryo-related debates are increasingly influencing public policy throughout the United States. Questions involving embryo personhood, embryo disposition, genetic testing, reproductive autonomy, and embryo research are no longer hypothetical. They are shaping legislation, litigation, and public discourse. The outcomes will influence not only the future of assisted reproductive technologies but also broader questions involving family formation, scientific innovation, and patient autonomy.

As someone who works in reproductive health policy—and as a mother whose family was built through IVF—I was reminded throughout the conference that embryo law is ultimately about people. Behind every legal theory, legislative proposal, and ethical framework are patients navigating infertility, families making deeply personal decisions, clinicians providing evidence-based care, and researchers advancing scientific understanding.

If there was a central lesson I took from Harvard’s Embryo Law and Ethics conference, it was that decisions about embryo law cannot be made in isolation from the people whose lives they affect. Reproductive medicine cannot afford to remain a passive observer as these debates unfold. The field has both an opportunity and an obligation to contribute its expertise, and I was pleased to see so many ASRM representatives, including Judith Daar, Susan Crockin, Emma Berens, and Joshua Romero, in participation. Conversations got real. Areas of disagreement and agreement were surfaced. This is precisely the type of interdisciplinary discourse that the moment demands.

Conferences such as this one create space for rigorous dialogue before policy choices are made and before legal frameworks become fixed. The CPL was proud to support this convening and remains committed to advancing evidence-based discussions that inform policy, protect access to reproductive healthcare, and serve the needs of patients and families. The future of reproductive medicine depends upon it.

Declaration of Interests

R.W.O. has nothing to disclose.


Articles from F&S Reports are provided here courtesy of Elsevier

RESOURCES